Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis

Clicks: 230
ID: 270093
2018
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Sofosbuvir plus velpatasvir is highly effective and safe for treating patients with hepatitis C virus genotypes 1, 2, 3, 4, 5 or 6 and advanced fibrosis or compensated cirrhosis.
Reference Key
t2018liversofosbuvir/velpatasvir Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Asselah T;Bourgeois S;Pianko S;Zeuzem S;Sulkowski M;Foster GR;Han L;McNally J;Osinusi A;Brainard DM;Subramanian GM;Gane EJ;Feld JJ;Mangia A;;
Journal liver international : official journal of the international association for the study of the liver
Year 2018
DOI DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/28756625
Keywords
hepatitis c National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine research support non-u.s. gov't female male aged middle aged Drug Administration Schedule Multicenter Study Retrospective Studies severity of illness index drug therapy combination antiviral agents / therapeutic use* chronic / complications chronic / drug therapy* hepacivirus / genetics sustained virologic response carbamates / therapeutic use* heterocyclic compounds 4 or more rings / therapeutic use* sofosbuvir / therapeutic use* tarik asselah pmid:28756625 doi:10.1111/liv.13534 stefan bourgeois alessandra mangia liver cirrhosis / drug therapy* liver cirrhosis / virology

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.